Zurück zu den Rankings

BGM Group Ltd. (BGM)

NEGATIVE
HealthcareDrug Manufacturers - Specialty & GenericChina

Fundamental

~22

Kurs

$0.25

Marktkapitalisierung

$100M

Teil 1 · Was das Unternehmen wert ist

Übersicht

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Begrenzte Finanzdaten verfügbar (37 % der Kennzahlen). Scores spiegeln möglicherweise die Fundamentaldaten dieses Unternehmens nicht genau wider.

Bilanz & Liquidität

Umsatz

$74M

Nettogewinn

$-39M

Freier Cashflow

-

Gesamtes Eigenkapital

$742M

Gesamtverbindlichkeiten

-

Current Ratio

1.24

Zinsdeckungsgrad

-

Schulden/EBITDA

-

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

Pre-revenueÜberbewertet
For a company classified as Pre-revenue, the appropriate models don't have enough data. The value below comes from the generic methods, which are less reliable for this kind of business: read it as an order of magnitude, and look at the range rather than the single number.

Innerer Wert

$0.10

Aktueller Kurs

$0.25

Sicherheitsmarge

-154.5%

Innerer-Wert-Spanne

$0.08 - $0.13

Bewertungsmethoden

Analyst price target:Not enough data to compute it
Discounted cash flow (DCF):$0.10
Earnings multiple (P/E):Not enough data to compute it
Graham growth formula:Not enough data to compute it
Earnings power value (EPV):Not enough data to compute it
Justified P/B:Not applicable to this type of company
Dividend discount (Gordon):Not applicable to this type of company
P/FFO, funds from operations:Not applicable to this type of company
Mid-cycle earnings:Not applicable to this type of company
Revenue multiple:Not enough data to compute it

Bewertungskennzahlen

P/E-Verhältnis

-

ROE

-7.0%

P/B-Verhältnis

0.15

P/FCF

31.32

Bruttomarge

16.6%

ROIC

-1.8%

Rentabilitäts-Radar

Value Creation (Economic Moat)

ROIC

-1.8%

WACC

14.5%

ROIC − WACC

-16.2 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamentalanalyse-Kriterien

Bestanden (2)

  • P/B Ratio 0.15
  • Current Ratio

Nicht bestanden (8)

  • Price CAGR -54.38%
  • ROIC -1.8%
  • Gross Margin 16.6%
  • P/FCF 31.32
  • DCF valuation (Overvalued)
  • ROE -7.0%
  • Revenue Growth 5Y -5.4%
  • Piotroski F-Score 0/9

Nicht verfügbar (17)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Debt/Equity ratio
  • Operating Margin NaN%
  • Positive Free Cash Flow
  • CapEx intensity
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • Analyst Consensus (Finnhub)
  • Earnings Surprise (Finnhub)
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)
  • Share Dilution (need 2+ years)
  • Net Margin Trend (invalid data)

Piotroski F-Score

0/9

Ernsthafte finanzielle Bedenken

score
criteria

Gewinnqualität

-

Niedrige Qualität: Rechnungslegung prüfen

Aktienverwässerung

-

Aktienrückkäufe. Aktionärsfreundlich

Unternehmensführung

Führungsteam

NamePositionAlter
Ms. Huandi ZhaoCo-Chief Executive Officer & Director40
Ms. Li HongCo-Chief Executive Officer-
Ms. Yaxuan ZhaiChief Financial Officer30

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Latest News

Recent headlines for BGM, sourced from Markets Gazette.

No recent news for BGM.